Immune system genes, including cytokines, are associated with schizophrenia risk. Polymorphisms in cytokine genes may also impact on blood levels of cytokines, which are altered in patients with schizophrenia. We performed a meta-analysis of case-control studies of cytokine and chemokine genes in schizophrenia that have not been considered in previous quantitative reviews. Methods: We identified articles by systematic searches of PubMed, PsycInfo, and ISI, and the reference lists of identified studies. For each cytokine or chemokine polymorphism, we performed an allele-and genotype-wise meta-analysis, using a random effects model. Results: Twenty-one independent studies met the inclusion criteria, comprising polymorphisms for the IL1B, IL2, IL4, IL6, sIL6R, MCP1, and TGFB1 genes. For IL6, the A allele (OR=0.95, 95% CI 0.91-0.99) and AA genotype (OR=0.65, 95% CI 0.50-0.85) for the rs1800795 polymorphism, and for sIL6R, the A allele (OR=0.96 95%, CI 0.92-1.00) and AA genotype (OR=0.72, 95% CI 0.55-0.94) the rs8192284 polymorphism were associated with significantly decreased schizophrenia risk. In the genotype-wise analysis for IL1B, homozygosity for either allele (AA: OR=1.91, 95% CI 1.60-2.27; and GG: OR=0.40, 95% CI 0.33-0.49) of the rs1143627 polymorphism was also significantly associated with schizophrenia risk. Conclusions: Associations between polymorphisms for the IL1B, IL6, and sIL6R genes and schizophrenia risk complement and extend previous findings regarding immune dysfunction in this disorder, including genome-wide association studies. Future studies of cytokine expression in schizophrenia should consider the effect of these polymorphisms. The finding of potential "protective" alleles may also be relevant for at-risk populations.
Clinical Implications
We found that polymorphisms in genes for IL1B, IL6, and sIL6R-but not IL2, IL4, MCP1, or TGFB1-were associated with schizophrenia risk. There was significant heterogeneity in these findings; however, the association remained significant in sensitivity analyses.
An important strength of our study is that we considered polymorphisms for a number of different cytokine or chemokine genes that have not been investigated in previous quantitative reviews. For the allele-wise analysis, we were able to include data from the large Psychiatric Genomics Consortium study of schizophrenia (30) . Of note, our findings for the IL6 and sIL6R genes remained significant in sensitivity analyses, which excluded this study, supporting the robustness of the association in smaller samples. Blood protein levels IL-1β, IL-6 are also abnormal in schizophrenia, and the sIL-6R enhances the biological activity of IL-6 (4). Thus, our work complements and extends previous findings regarding immune dysfunction in this disorder, including genome-wide association studies. Our findings also directly inform on future studies of blood cytokine expression in schizophrenia, which should consider the effect of these polymorphisms.
Taken together, our results complement and extend previous findings regarding immune dysfunction in schizophrenia, and inform on future studies of cytokine expression in schizophrenia. Future studies of inflammation should consider the effects of cytokine gene polymorphisms on schizophrenia risk, cytokine levels, and other clinical features of the disorder. Replicated findings may contribute to more personalized medicine for patients with schizophrenia.
Polymorphisms in cytokine genes may impact not only on schizophrenia risk, but also blood levels of cytokines. For example, Zakharyan et al. (8) found that the rs1800795*C allele of the interleukin-6 (IL6) gene was significantly more common in patients with schizophrenia than controls, but that both patients and controls homozygous for the G allele had significantly higher blood IL-6 protein levels. Despite the evidence for cytokine network alterations in schizophrenia, there is tremendous between-study heterogeneity in this research area. Genetic effects on cytokine network alterations in schizophrenia represent an important understudied area.
We performed a meta-analysis of case-control studies of cytokine and chemokine genes in schizophrenia that have not been considered in previous quantitative reviews. The primary aim of the meta-analysis was to identify other cytokine and/or chemokine gene polymorphisms associated with schizophrenia risk that may also contribute to alterations in blood levels of these proteins, and in doing so, inform future studies of cytokines and chemokines in schizophrenia.
Methods

Study Selection
Studies of cytokine (or chemokine) genes and schizophrenia were systematically searched using MEDLINE (National Center for Biotechnology Information, US National Library of Medicine, Bethesda, Maryland), PsycInfo (via Ovid, American Psychological Association, Washington, DC), and Thomson Reuters (formerly Institute for Scientific Information) Web of Knowledge (Science Citation Index and Social Sciences Citation Index, Thomson Reuters, Charlottesville, Virginia) in July 2014. The primary search strategy was "(schizophrenia or psychosis) and (inflammation or cytokine or chemokine or interleukin or interferon or tumor immune cells, and exert their effects by binding specific cytokine receptors on a variety of target cells. Cytokine receptors also exist in soluble forms, which can inhibit (e.g., soluble interleukin-2 receptor [sIL-2R]) or enhance (e.g., sIL-6R) the biological activity of cytokines. There are also endogenous cytokine receptor antagonists (e.g., IL-1 receptor antagonist ), which compete with cytokines for membrane receptors. Cytokines are key regulators of acute and chronic inflammation, a complex but vital biological response that impacts all organ systems. Cytokines help coordinate the function of both the innate and adaptive components of the immune system as well as a host of other physiological processes throughout the body.
Several recently published meta-analyses investigated polymorphisms in the genes for IL-1beta (IL1B) (9, 10), IL10 (11), and tumor necrosis factor-alpha (TNFα) (12) and schizophrenia risk. Across four studies, Xu et al. (10) found a significant genotype-wise association between the rs1143634 polymorphism of the IL1B gene and schizophrenia risk in population-based studies and Caucasian subjects. By contrast, they did not find an association between either the rs1800587 polymorphism of the IL1A gene or the rs1794068 polymorphism of the IL1RA gene and schizophrenia susceptibility. Shibuya et al. (9) did not find an association between the rs16944 polymorphism of the IL1B gene and schizophrenia risk across 16 studies. In a meta-analysis of 11 studies, Gao et al. (11) found a significant allele-wise and genotypewise association between the rs1800872 polymorphism of the IL10 gene and schizophrenia risk, but no associations with either the rs1800096 or rs1800871 polymorphisms. Across 21 studies, Qin et al. (12) did not find an association between the rs1800629 polymorphism of the TNFα gene and schizophrenia risk. necrosis factor) and gene. " Initial search results returned 320 articles from MEDLINE, 154 from PsycInfo, and 311 from Thomson Reuters. From these sources, as well as a manual review of reference lists, we identified 109 potential studies for inclusion. We did not employ formal search software and all publications were retrieved and examined in full text. Based on a preliminary review of these matches, 25 studies presented data on cytokine genes and warranted further consideration (8, 9, . These studies are summarized in Table 1. The majority of initial matches were excluded as they: 1) were review articles, or 2) did not present data on cytokine genes, or 3) did not study schizophrenia.
The inclusion criteria were: 1) case-control studies with patients with schizophrenia compared to healthy controls, 2) studies in English, 3) specific cytokine genetic polymorphisms were determined, and 4) original allelotype or genotype data available. Studies were excluded if they: 1) used a family-based design, 2) did not include controls (i.e., cases only), or 3) genotype frequencies for control subjects were not in Hardy-Weinberg Equilibrium. We did not include cytokines investigated in recently published meta-analysis, including selected polymorphisms for IL1B (8, 9), IL10 (10), and TNFα (11) genes. After independent searches, detailed review of study methods by two authors (ZH and BJM), 21 studies met the inclusion criteria, which are summarized in Table 1 . Three studies were excluded from the final analysis due to genotype frequencies for control subjects not being in 19, 25, 26) . Data repository access to findings from the Schizophrenia Psychiatric Genomics Consortium (30) was obtained. This study had available data for allelotypes only, and was included. There was universal agreement on the included studies. A flow chart summarizing the study selection process is presented in Figure 1 .
Data Extraction and Meta-Analysis
Data were extracted (diagnostic criteria, total number of cases and controls, region and race of participants, and allele and genotype number and frequency) for each cytokine polymorphism in each study. The Schizophrenia Psychiatric Genomics Consortium study (30) did not have data on raw numbers for alleles, but included an odds ratio and standard error for allelotype data, from which 95% confidence intervals (95% CIs) could be calculated, thus facilitating inclusion of the data. One author (ZH) extracted all data, which were independently verified by another author (BJM). Hardy-Weinberg Equilibrium (HWE) was assessed in control groups using a chi-square goodness-of-fit test (with a pvalue <0.05 representing significant deviation from HWE). For each polymorphism for each cytokine or chemokine, we performed both an allele-wise and a genotype-wise analysis. Allele 1 represented the major allele, and allele 2 represented the minor allele. The allele-wise analysis compared the frequency of allele 1 versus allele 2. The two genotype-wise analyses were 1) genotype 11 versus (genotypes 12+22), and 2) genotype 22 versus (genotypes 11+12). Effect size estimates (odds ratios [ORs] and 95% confidence intervals [95% CIs]) were aggregated utilizing the random effects method of DerSimonian and Laird (36). Random effects methods are considered to be more representative of real-world data in comparison to the alternative fixed-effect approach (37) and provide a more conservative estimate of the average weighted effect size (38). Random effects models also yield their actual first-error rate while fixed-effect models tend to inflate their first-error rate. Confidence intervals obtained by fixed-effect models are also biased and their actual coverage rate is smaller than their nominal coverage rate (39). One study of the G913C polymorphism of the TGFB1 gene that otherwise met the inclusion criteria could not be analyzed in the random effects meta-analysis because all patients and controls were homozygous for the same genotype (16), which results in an OR and 95% CI that is undefined. The main statistical hypothesis was that the ORs for the allelotypes and genotypes of patients with schizophrenia versus controls equal 1.00.
The meta-analysis procedure also calculates an χ 2 value for the heterogeneity in effect size estimates, which is based on Cochran's Q-statistic (40), and I 2 , the proportion of the variation in effect size attributable to between-study heterogeneity. Between-study heterogeneity χ 2 was considered significant for p<0.10 (41). For any polymorphism with three or more studies, a significant odds ratio, and significant between-study heterogeneity we performed a sensitivity analysis. This was done by removing one study at a time 
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Studies included in the meta-analysis (Schizophrenia Psychiatric Genomics Consortium data on allelotypes only.)
Figure 1 Flowchart of the Study Selection Process
and repeating the meta-analysis procedure to examine its impact on the odds ratio and between-study heterogeneity (42). When possible, for a given cytokine polymorphism, the potential for publication bias was examined by means of Sterne's funnel plot analysis (43) and Egger's regression intercept (44). The statistical analyses were performed in Stata 10.0 (StataCorp LP, College Station, TX) (45). All tests were two-sided, and p-values were considered statistically significant at the α=0.05 level. Given the exploratory nature of this meta-analysis, we did not correct for multiple comparisons.
Results
As described in Table 1 , search procedures yielded twenty-one independent studies. These studies included polymorphisms for IL1B, IL2, IL4, IL6, sIL6R, monocyte chemoattractant protein-1 (MCP1), and TGFB1 genes. We included selected polymorphisms for the IL1B gene due to the availability of new studies and/or polymorphisms not considered in the previous meta-analysis (10). We excluded the following studies due to significant deviations from HWE: Paul-Samojedny et al. (2013) (26) There were seven studies and four different polymorphisms (rs1143627, rs1143630, rs1143633, and rs1143634) for the IL1B gene, two studies of one polymorphism (rs2069762) for the IL2 gene, four studies of one polymorphism (rs2243250) for the IL4 gene, six studies of one polymorphism (rs1800795) for the IL6 gene, three studies of one polymorphism (rs8192284) for the sIL6R gene, four studies for one polymorphism (rs1024611) for the MCP1 gene, and two studies of two different polymorphisms (rs1800470 and rs1800471) for the TGFB1 gene. We were not able to perform meta-analyses for the IL12B and IFNγ gene because only one study for each gene met the inclusion criteria. Table 2 presents the results of meta-analyses. In the allele-wise analysis, the rs1800795 polymorphism for the IL6 gene (OR=0.95, 95% CI=0.91-0.99) and the rs8192284 polymorphism for the sIL6R gene (OR=0.96, 95% CI=0.92-1.00) were associated with significantly decreased odds of schizophrenia. Between-study heterogeneity was significant for both of these polymorphisms (p≤0.01 for each). In sensitivity analyses, the odds ratio remained significant and the between-study heterogeneity was no longer significant following removal of one study (30) for both the IL6 (OR=0.78, 95% CI=0.65-0.94, p<0.01) and sIL6R (OR=0.76, 95% CI=0.64-0.91, p<0.01) genes. No other polymorphisms were significantly associated with schizophrenia in the allele-wise analysis.
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In the genotype-wise analysis for the rs1143627 polymorphism for the IL1B gene, homozygosity for the major allele was associated with significantly increased odds of schizophrenia (OR=1.91, 95% CI 1.60-2.27, p<0.01), and homozygosity for the minor allele was associated with a significantly decreased odds of schizophrenia (OR=0.40, 95% CI 0.33-0.49, p<0.01), with significant between-study heterogeneity. In a sensitivity analyses, the odds ratio remained significant and the between-study heterogeneity was no longer significant following removal of one study (Shibuya et al., 2014 ) (9). The genotype for the rs1800795 polymorphism for the IL6 gene was associated with significantly decreased odds of schizophrenia (GG vs. CC+GC, OR=0.65, 95% CI=0.50-0.85, p<0.01), and between-study heterogeneity was not significant. Genotype for the rs8192284 polymorphism for the sIL6R gene was also associated with significantly decreased odds of schizophrenia (AA vs. AC+CC, OR=0.72, 95% CI=0.55-0.94, p=0.02), and between-study heterogeneity was not significant. All other polymorphisms showed no significant genotype-wise associations. Forest plots for the rs1800795 polymorphism for the IL6 gene, the rs8192284 polymorphism for the sIL6R gene, and the rs1143627 polymorphism for the IL1B gene are shown in Figure 2 . There were an insufficient number of studies to assess for publication bias for the sIL6R and IL1B polymorphisms (42). However, for the IL6 gene, the funnel plot (see Figure 3) and results of Egger's test (intercept -0.03, 95% CI -4.72-4.67, p=0.99) showed no evidence for potential publication bias.
Discussion
An important strength of our study is that we considered polymorphisms for a number of different cytokine or chemokine genes that have not been investigated in previous quantitative reviews. For the allele-wise analysis, we were able to include data from the large Psychiatric Genomics Consortium study of schizophrenia (30). Of note, our findings for the IL6 and sIL6R genes remained significant in sensitivity analyses, which excluded this study, supporting the robustness of the association in smaller samples. Blood protein levels IL-1β, IL-6 are also abnormal in schizophrenia, and the sIL-6R enhances the biological activity of IL-6 (4). Thus, our work complements and extends previous findings regarding immune dysfunction in this disorder, including genome-wide association studies. Our findings also directly inform on future studies of blood cytokine expression in schizophrenia, which should consider the effect of these * Denotes number of studies for allele-wise analysis, as genotype-wise data not available for the Schizophrenia PGC 2011 study. 2C IL1B (rs1143627 polymorphism) gene-genotype analysis polymorphisms. We also excluded studies that had significant deviations from HWE in controls, which may bias effect size estimates for genes in meta-analysis (46). There are always limitations to studies. Our findings must be interpreted with some caution in light of the small number of studies for some cytokine or chemokine genes. Due to the small number of studies, we were not able to perform meta-regression analyses to explore possible moderating variables (e.g., sex, race, geographic location, and genotyping method), which warrant investigation in future studies. We were not able to control for other potential confounding factors such as the uniformity of diagnosis of schizophrenia across studies (and the absence of diagnosis in controls). The impact of these factors on the associations is unclear.
Gene
Additional studies are needed to investigate polymorphisms in other cytokine genes that may be associated with schizophrenia risk and cytokine network expression. We previously found alterations in blood sIL-2R, IL-12, and IFN-γ protein levels in schizophrenia (Miller et al., 2011) (4) . Sufficient data for meta-analysis were not available for polymorphisms in these cytokine genes, which should be explored. Relationships between cytokine gene polymorphisms and other aspects of schizophrenia have not been investigated. One previous study found that an IL6 gene polymorphism also impacts on blood IL-6 protein levels (8). Another study found that an sIL6R gene polymorphism is associated with higher blood protein levels of both sIL-6R and IL-6 in patients with schizophrenia (28). Given evidence for alterations in blood cytokine levels in schizophrenia (4-6), future studies should investigate the effects of these polymorphisms on protein expression in the peripheral blood and CNS. Whether cytokine gene polymorphisms are associated with other clinical features in schizophrenia, such as psychopathology, cognition, brain volumes, treatment response, or illness course, is also unknown. Outside of schizophrenia, polymorphisms in genes for IL1B and TNFα may impact on risk of depression, and polymorphisms for IL1B and IL6 genes may impact on antidepressant response (47). Future studies in schizophrenia could investigate relationships between cytokine gene polymorphisms and response to antipsychotics or other adjunctive treatments.
Taken together, our results complement and extend previous findings regarding immune dysfunction in schizophrenia, and inform on future studies of cytokine expression in schizophrenia. Future studies of inflammation should consider the effects of cytokine gene polymorphisms on schizophrenia risk, cytokine levels, and other clinical features of the disorder. Replicated findings may contribute to more personalized medicine for patients with schizophrenia. 
